| |  Online-Ressource |
|---|
| Verfasst von: | Christopoulos, Petros [VerfasserIn]  |
|---|
| | Dietz, Steffen [VerfasserIn] |
|---|
| | Kirchner, Martina [VerfasserIn] |
|---|
| | Volckmar, Anna-Lena [VerfasserIn] |
|---|
| | Endris, Volker [VerfasserIn] |
|---|
| | Neumann, Olaf [VerfasserIn] |
|---|
| | Heußel, Claus Peter [VerfasserIn] |
|---|
| | Herth, Felix [VerfasserIn] |
|---|
| | Eichhorn, Martin E. [VerfasserIn] |
|---|
| | Meister, Michael [VerfasserIn] |
|---|
| | Budczies, Jan [VerfasserIn] |
|---|
| | Allgäuer, Michael [VerfasserIn] |
|---|
| | Leichsenring, Jonas [VerfasserIn] |
|---|
| | Bischoff, Helge [VerfasserIn] |
|---|
| | Schirmacher, Peter [VerfasserIn] |
|---|
| | Thomas, Michael [VerfasserIn] |
|---|
| | Sültmann, Holger [VerfasserIn] |
|---|
| | Stenzinger, Albrecht [VerfasserIn] |
|---|
| Titel: | Detection of TP53 mutations in tissue or liquid rebiopsies at progression identifies ALK+ lung cancer patients with poor survival |
|---|
| Verf.angabe: | Petros Christopoulos, Steffen Dietz, Martina Kirchner, Anna-Lena Volckmar, Volker Endris, Olaf Neumann, Simon Ogrodnik, Claus-Peter Heussel, Felix J. Herth, Martin Eichhorn, Michael Meister, Jan Budczies, Michael Allgäuer, Jonas Leichsenring, Tomasz Zemojtel, Helge Bischoff, Peter Schirmacher, Michael Thomas, Holger Sültmann, Albrecht Stenzinger |
|---|
| E-Jahr: | 2019 |
|---|
| Jahr: | 21 January 2019 |
|---|
| Umfang: | 9 S. |
|---|
| Teil: | volume:11 |
|---|
| | year:2019 |
|---|
| | number:1 |
|---|
| | extent:9 |
|---|
| Fussnoten: | Gesehen am 26.06.2019 ; Im Titel ist das Zeichen "+" hochgestellt |
|---|
| Titel Quelle: | Enthalten in: Cancers |
|---|
| Ort Quelle: | Basel : MDPI, 2009 |
|---|
| Jahr Quelle: | 2019 |
|---|
| Band/Heft Quelle: | 11(2019,1) Artikel-Nummer 124, 9 Seiten |
|---|
| ISSN Quelle: | 2072-6694 |
|---|
| Abstract: | Anaplastic lymphoma kinase (ALK) sequencing can identify resistance mechanisms and guide next-line therapy in ALK+ non-small-cell lung cancer (NSCLC), but the clinical significance of other rebiopsy findings remains unclear. We analysed all stage-IV ALK+ NSCLC patients with longitudinally assessable TP53 status treated in our institutions (n = 62). Patients with TP53 mutations at baseline (TP53mutbas, n = 23) had worse overall survival (OS) than patients with initially wild-type tumours (TP53wtbas, n = 39, 44 vs. 62 months in median, p = 0.018). Within the generally favourable TP53wtbas group, detection of TP53 mutations at progression defined a “converted” subgroup (TP53mutconv, n = 9) with inferior OS, similar to that of TP53mutbas and shorter than that of patients remaining TP53 wild-type (TP53wtprogr, 45 vs. 94 months, p = 0.043). Progression-free survival (PFS) under treatment with tyrosine kinase inhibitors (TKI) for TP53mutconv was comparable to that of TP53mutbas and also shorter than that of TP53wtprogr cases (5 and 8 vs. 13 months, p = 0.0039). Fewer TP53wtprogr than TP53mutbas or TP53mutconv cases presented with metastatic disease at diagnosis (67% vs. 91% or 100%, p < 0.05). Thus, acquisition of TP53 mutations at progression is associated with more aggressive disease, shorter TKI responses and inferior OS in ALK+ NSCLC, comparable to primary TP53 mutated cases. |
|---|
| DOI: | doi:10.3390/cancers11010124 |
|---|
| URL: | Volltext ; Verlag: https://doi.org/10.3390/cancers11010124 |
|---|
| | Volltext: https://www.mdpi.com/2072-6694/11/1/124 |
|---|
| | DOI: https://doi.org/10.3390/cancers11010124 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) |
|---|
| | overall survival |
|---|
| | progression-free survival |
|---|
| | tumor protein p53 gene (TP53) mutation |
|---|
| | tyrosine kinase inhibitor |
|---|
| K10plus-PPN: | 1667973045 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
| |
|
|---|
| | |
|---|
| Lokale URL UB: |  Zum Volltext |
|---|
Detection of TP53 mutations in tissue or liquid rebiopsies at progression identifies ALK+ lung cancer patients with poor survival / Christopoulos, Petros [VerfasserIn]; 21 January 2019 (Online-Ressource)
